Publications by authors named "Clemens Krepler"

57Publications

Outcomes of retreatment with anti-PD-1 monotherapy after response to first course in patients with cutaneous melanoma.

Future Oncol 2020 Jul 15;16(20):1441-1453. Epub 2020 May 15.

Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2020-0314DOI Listing
July 2020

Acetylsalicylic Acid Governs the Effect of Sorafenib in -Mutant Cancers.

Clin Cancer Res 2018 03 1;24(5):1090-1102. Epub 2017 Dec 1.

Dermatology Research Centre, The University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-2118DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844814PMC
March 2018

The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.

Eur J Cancer 2017 03 3;73:85-92. Epub 2017 Feb 3.

Center for Dermatooncology, Department of Dermatology, University Hospital Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.12.010DOI Listing
March 2017

MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.

Eur J Cancer 2017 03 3;73:93-101. Epub 2017 Feb 3.

Center for Dermatooncology, Department of Dermatology, Liebermeisterstr. 25, University Hospital Tübingen, 72076 Tübingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.12.012DOI Listing
March 2017

Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in -Mutant Ovarian Cancer Models.

Clin Cancer Res 2017 06 19;23(12):3097-3108. Epub 2016 Dec 19.

Penn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Pennsylvania, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-2273DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474193PMC
June 2017

An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.

Cancer Cell 2016 09 11;30(3):485-498. Epub 2016 Aug 11.

Department of Oncological Sciences, Department of Dermatology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.06.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021590PMC
September 2016

Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma.

Mol Cancer Res 2016 09 13;14(9):767-75. Epub 2016 Jun 13.

Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-16-0099DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025362PMC
September 2016

Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R.

PLoS One 2014 29;9(1):e84417. Epub 2014 Jan 29.

Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria ; Division of Hematology & Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0084417PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906015PMC
September 2014

Highlights of melanoma research presented at the 49th annual meeting of the American Society of Clinical Oncology in Chicago, 2013.

Pigment Cell Melanoma Res 2014 Jan 1;27(1):E1-5. Epub 2013 Nov 1.

Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12182DOI Listing
January 2014

Neoplastic stem cells: current concepts and clinical perspectives.

Crit Rev Oncol Hematol 2010 Nov 25;76(2):79-98. Epub 2010 Feb 25.

Bone Marrow Transplantation Unit, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2010.01.001DOI Listing
November 2010

Loss of novel mda-7 splice variant (mda-7s) expression is associated with metastatic melanoma.

J Invest Dermatol 2004 Sep;123(3):583-8

Department of Clinical Pharmacology, Section of Experimental Oncology/Molecular Pharmacology, University of Vienna, Vienna General Hospital, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.0022-202X.2004.23321.xDOI Listing
September 2004

CpG oligonucleotides elicit antitumor responses in a human melanoma NOD/SCID xenotransplantation model.

J Invest Dermatol 2004 Feb;122(2):387-91

Department of Dermatology, Division of General Dermatology, University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.0022-202X.2004.22202.xDOI Listing
February 2004

Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice.

Antisense Nucleic Acid Drug Dev 2002 Dec;12(6):359-67

Department of Clinical Pharmacology, Section of Experimental Oncology/Molecular Pharmacology, University of Vienna, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/108729002321082438DOI Listing
December 2002